Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medivation, Inc.

http://www.medivation.com/

Latest From Medivation, Inc.

Sanfilippo Syndrome Patients, Drug Developers At Odds With US FDA Guidance

Agency recommendation for randomized controlled trials in ultra-rare pediatric disease is unworkable for various reasons, say advocates and sponsors who seek use of the accelerated approval pathway based on changes in heparan sulfate levels.

Drug Approval Standards Gene Therapy

Riding US Approval, Junshi, Coherus Swing For PD-1 Combo Therapy Partnerships

Antibodies targeting TIGIT, IL-27, CCR8 and BTLA from the Chinese and US firms are among the first batch of combination candidates expected to expand the indications of anti-PD-1 antibody Loqtorzi beyond the rare condition of nasopharyngeal carcinoma.

Cancer ImmunoOncology

Lebrikizumab Among Nine Drugs To Get EMA Nod; PTC Faces Disappointment For Translarna

The European Medicines Agency has OKd nine new medicines for EU-wide approval, but recommended against renewing the conditional marketing authorization of two drugs. 

Europe Drug Review

Potential Blockbuster Lebrikizumab Among Latest Drugs Up For Decision On EU Approval

The European Medicines Agency  is set to decide whether to back EU marketing approval for eight new drugs.

Europe Drug Review
See All

Company Information

UsernamePublicRestriction

Register